LifePlus Stem Cells, a provider of innovative stem cell advancements, specialising in regenerative rehabilitation announces their first injection of its umbilical cord-derived allogeneic mesenchymal stem cells. Using a unique and highly regulated manufacturing process, LifePlus Stem Cells is able to provide patients and clinicians with the world’s purest allogeneic mesenchymal stem cells – achieving purity levels of well over 80%.
February 1, 2021, London, UK — “This is an exciting time for LifePlus Stem Cells, the first injection of an allogeneic product expands our capabilities as a regenerative rehabilitation service, offering doctors and prescribers with the most advanced stem cell technology,” said Chris Schiel, Chief Executive Officer of LifePlus Stem Cells. “We have already received significant interest from physicians across the UK, expressing an interest in our exceptional quality and highly regulated products, including Dr Aamer Khan, an award winning doctor and renowned surgical pioneer”.
“After working with Stem Cell therapies for more than 12 years we are very excited to be able to introduce LifePlus technology to our treatment catalogue,” said Dr Khan.
The very first injection was delivered on January the 20th 2021, by LifePlus’ Consultant Physiotherapist, Suresh Sudula at the Harley Street Skin Clinic in London. The patient was suffering from arthritis following injury for several years, enduring pain and reduced mobility.
The allogeneic mesenchymal stem cells were transported to the CQC registered clinic using a specialist courier, cells are contained in dry ice and stored at -80°C during transportation, once opened the cells are quickly delivered to the patient. In this case the patient had the cells delivered via site injection, using ultrasound guided imaging.
Depending on the condition stem cells can also be delivered by intravenous drip. The treatment took approximately 20 minutes, the patient will be followed up at three, six and twelve months for evaluation.
About LifePlus Stem Cells
LifePlus are licensed to procure adipose tissue for the manufacture of an unlicensed medicinal product, in accordance with our HTA licence and in line with the Human Tissue (Quality and Safety For Human Application) Regulations 2007 (as amended). LifePlus uses an MHRA licensed facility to manufacture medicine grade cell therapy products as well as the banking of autologous stem cells.
LifePlus Stem Cells are delivered under prescription only as an unlicensed medicine. The medicine can be administered intradermally, intra-articulately, and intravenously. LifePlus Clinics Ltd (T/as Life Plus Stem Cells) is situated in central London and was first established in July 2019 in conjunction with Professor Ash Mosahebi as LifePlus Medical Director and in collaboration with other stem cell experts.
Read more about Dr Aamer Khan – www.harleystreetskinclinic.com